Survival outcomes of the study population. PFS (A) and OS (B) in the overall patient population by physicians’ ITT of prophylactic HD-MTX. PFS (C) and OS (D) in the IPI low-risk group. PFS (E) and OS (F) in the IPI intermediate-risk group. PFS (G) and OS (H) in the IPI high-risk group.